Could a higher stem cell dose beat back lymphoma?

NCT ID NCT02570542

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving more stem cells during an autologous transplant helps people with relapsed or refractory diffuse large B-cell lymphoma recover better and stay cancer-free longer. About 59 adults who have already tried one chemotherapy will get high-dose chemo (BEAM) followed by a stem cell infusion. Researchers will compare different stem cell doses to see which leads to better immune recovery and longer time without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cells (CD34+ cells) collected after plerixafor mobilization, followed by BEAM chemotherapy
What this could lead to: If successful, this could help doctors choose the best stem cell dose to improve recovery and delay lymphoma progression after transplant.
What could go wrong: This is a small, early-phase study with only 59 participants, so results may not apply to all patients. The transplant itself carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Contacts and locations

Locations

Columbia University

New York, New York, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up Only)

Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Bergen (Consent and Follow Up Only)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (Consent and Follow-up Only)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Consent and Follow up Only)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Consent and Follow up Only)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Northwell Health (Data collection only)

Manhasset, New York, 11030, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States
Texas Transplant Institute

San Antonio, Texas, 78229, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198-7680, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.